|
| Press Releases |
|
 |
|
| Tuesday, December 1, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Monday, November 30, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Wednesday, November 11, 2020 |
|
|
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. more info >> |
|
| Monday, November 2, 2020 |
|
|
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity |
| BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
CEVA Joins Windrose To Test Long-Haul EV Trucking in China
Jun 28, 2025 01:00 HKT/SGT
|
|
|
CEVA攜手Windrose測試中國長途電動卡車運輸
Jun 28, 2025 01:00 HKT/SGT
|
|
|
CEVA携手Windrose测试中国长途电动卡车运输
Jun 28, 2025 01:00 HKT/SGT
|
|
|
"Tang Vogue Beyond the Horizons: A Golden Era of Multicultural Integration and Openness" exhibition opens
Jun 27, 2025 22:36 HKT/SGT
|
|
|
「唐風萬里：多元交融開放的盛世」展覽開幕
Jun 27, 2025 22:24 HKT/SGT
|
|
|
「唐风万里：多元交融开放的盛世」展览开幕
Jun 27, 2025 22:07 HKT/SGT
|
|
|
Prime Minister Paetongtarn Positions Thailand as Regional AI Ethics Leader: Official Launch of AIGPC at the UNESCO Global Forum on the Ethics of AI 2025
Jun 27, 2025 17:00 HKT/SGT
|
|
|
Honda、2025年5月度 四輪車 生産・販売・輸出実績を発表
Jun 27, 2025 15:15: JST
|
|
|
トヨタ、2025年5月 販売・生産・輸出実績を発表
Jun 27, 2025 13:35: JST
|
|
|
富士通のヘッドレスコマースがファミリーマートの新デジタルコマース事業「ファミマオンライン」を実現
Jun 27, 2025 11:00: JST
|
|
|
GA-ASI Announces Investment in Dutch Technology Innovator Arceon
Jun 27, 2025 01:00 HKT/SGT
|
|
|
GA-ASI 宣布投資荷蘭科技創新公司 Arceon
Jun 27, 2025 01:00 HKT/SGT
|
|
|
IBI Announces 23-Fold Surge in Net Profit for FY2025
Jun 26, 2025 22:37 HKT/SGT
|
|
|
IBI公佈2025財年淨利潤大幅增長23倍 在充滿挑戰的環境中實現強勁業績
Jun 26, 2025 22:24 HKT/SGT
|
|
|
IBI公布2025财年净利润大幅增长23倍 在充满挑战的环境中实现强劲业绩
Jun 26, 2025 22:08 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
